Asymmetric Dimethylarginine (ADMA) in Pediatric Renal Diseases: From Pathophysiological Phenomenon to Clinical Biomarker and Beyond

Asymmetric dimethylarginine (ADMA), an endogenous nitric oxide (NO) synthase inhibitor, inhibits NO synthesis and contributes to the pathogenesis of many human diseases. In adults, ADMA has been identified as a biomarker for chronic kidney disease (CKD) progression and cardiovascular risk. However,...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Chien-Ning, Tain, You-Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8535118/
https://www.ncbi.nlm.nih.gov/pubmed/34682102
http://dx.doi.org/10.3390/children8100837

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8535118/
https://www.ncbi.nlm.nih.gov/pubmed/34682102
http://dx.doi.org/10.3390/children8100837

Ejemplares similares